1. ALLA AKTIER
  2. NYHETER
  3. BBS-BIOACTIVE BONE SUBSTITUTES

BBS-Bioactive Bone Substitutes

Nyheter BBS-Bioactive Bone Substitutes Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

MARKN.

BBS-Bioactive Bone Substitutes Plc | Company Release | November 29, 2024 at 15:00:00 EET

BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

Production Director and the member of management team Kimmo Tyni has decided to resign from BBS and move to a new position outside the Company. Tyni will continue in his position until December 31, 2024.

Production Director Kimmo Tyni: "I am grateful for the opportunity to be part of this journey and to collaborate with a talented team. I am eagerly looking forward to new challenges and wish the Company and all its skilled employees success in the future as well."

CEO Juliusz Rakowski: "I thank Kimmo for his contribution in preparing the Reisjärvi Production Site for the commercial phase. We wish him all the best in his future challenges."

For more information, please contact:
Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

Distribution
Nasdaq Helsinki
https://www.bbs-artebone.fi/

BBS in brief
BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

Attachments
BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company

Datum 2024-11-29, kl 14:00
Källa MFN
Bifogade filer
BBS-Bioactive Bone Substitutes Plc: Production Director Kimmo Tyni resigns from the Company